{
  "meta": {
    "title": "65_Platelet_Disorders",
    "url": "https://brainandscalpel.vercel.app/65-platelet-disorders-196a1366.html",
    "scrapedAt": "2025-11-30T06:57:33.744Z"
  },
  "questions": [
    {
      "id": 82050,
      "choices": [
        {
          "id": 287116,
          "text": "JAK2"
        },
        {
          "id": 287117,
          "text": "MPL"
        },
        {
          "id": 287118,
          "text": "CALR"
        },
        {
          "id": 287119,
          "text": "All the above"
        }
      ],
      "text": "Which of the gene mutations is associated with essential thrombocytosis ?",
      "unique_key": "Q5920292",
      "question_audio": null,
      "question_video": null,
      "map_id": 34079680,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Essential thrombocytosis (ET) is a myeloproliferative disorder primarily characterized by an elevated platelet count. The three gene mutations most commonly associated with ET are JAK2, MPL, and CALR. These mutations play a key role in the abnormal regulation of platelet production in the bone marrow. The JAK2 V617F mutation is found in a significant proportion of patients with ET, particularly in those with features of polycythemia vera. The MPL mutation affects the thrombopoietin receptor, which is important for regulating platelet production. The CALR mutation is associated with a substantial portion of ET cases, particularly in patients without JAK2 or MPL mutations. Hence, the correct answer is D since all three mutations (JAK2, MPL, and CALR) can be associated with essential thrombocytosis. Incorrect Answers: A. JAK2: While JAK2 mutations, particularly JAK2 V617F, are one of the most common mutations in myeloproliferative disorders, they are not exclusive to essential thrombocytosis. JAK2 mutations can also be present in polycythemia vera and other myeloproliferative diseases. Therefore, while JAK2 mutations can be present in ET, it is not the only mutation associated with the disease. B. MPL: The MPL mutation is associated with essential thrombocytosis, but not all ET patients carry this mutation. It is less common than the JAK2 mutation but is still a contributing factor to the development of ET. Therefore, MPL mutations are one of the potential causes of ET but do not explain the full range of cases. C. CALR: CALR mutations are indeed linked to essential thrombocytosis, especially in cases where JAK2 and MPL mutations are absent. However, CALR mutations are not the sole cause of ET, and many patients with ET do not have CALR mutations, making it an incomplete answer on its own.",
      "correct_choice_id": 287119,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41820551705130747/41820551705130747.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41820551705130747/41820551705130747.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 82051,
      "choices": [
        {
          "id": 287120,
          "text": "Iron deficiency anaemia"
        },
        {
          "id": 287121,
          "text": "Polycythemia vera"
        },
        {
          "id": 287122,
          "text": "Inflammatory bowel disease"
        },
        {
          "id": 287123,
          "text": "All the above"
        }
      ],
      "text": "Thrombocytosis may be a feature of ?",
      "unique_key": "Q2341507",
      "question_audio": null,
      "question_video": null,
      "map_id": 34549696,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Thrombocytosis, which refers to an elevated platelet count, can be a feature of various conditions. It is not specific to one disease and can be found in multiple medical conditions. In iron deficiency anemia, thrombocytosis is a common compensatory response to the anemia, although the mechanism is not fully understood. In polycythemia vera, a myeloproliferative disorder, thrombocytosis can occur as part of the abnormal overproduction of blood cells, including platelets. Inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, can lead to secondary thrombocytosis due to inflammation, which stimulates platelet production. Therefore, all of these conditions can present with thrombocytosis, making D the correct answer. Incorrect Answers: A. Iron deficiency anemia: Thrombocytosis is often seen in iron deficiency anemia as a reactive response. When the body is deficient in iron, the bone marrow may increase production of not only red blood cells but also platelets. Thus, thrombocytosis is a feature of iron deficiency anemia, but it is part of a broader spectrum of conditions. B. Polycythemia vera: Polycythemia vera is a myeloproliferative disorder where there is an overproduction of red blood cells, and thrombocytosis is often a part of this disorder. However, thrombocytosis is not exclusive to polycythemia vera and can also be seen in other conditions, as mentioned. C. Inflammatory bowel disease: Inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis can cause a reactive thrombocytosis due to chronic inflammation. This is a common finding in patients with active disease or flare-ups, but it is not specific to IBD alone.",
      "correct_choice_id": 287123,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36184911705130759/36184911705130759.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36184911705130759/36184911705130759.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 82052,
      "choices": [
        {
          "id": 287124,
          "text": "1-4"
        },
        {
          "id": 287125,
          "text": "5-14"
        },
        {
          "id": 287126,
          "text": "15-30"
        },
        {
          "id": 287127,
          "text": "40-60"
        }
      ],
      "text": "Maximum risk of Heparin Induced Thrombocytopenia is …….. days following heparin exposure",
      "unique_key": "Q7130445",
      "question_audio": null,
      "question_video": null,
      "map_id": 34187967,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) 5-14 The maximum risk for Heparin-Induced Thrombocytopenia (HIT) occurs 5-14 days after heparin exposure. HIT is a rare but serious immune-mediated complication that involves the formation of antibodies against heparin-platelet factor 4 complexes. These antibodies activate platelets, leading to thrombocytopenia and an increased risk of thrombosis. The onset of HIT typically occurs about 5-14 days after exposure to heparin, although it can happen earlier in patients who have had prior exposure to heparin within the last 3 months. Incorrect Responses: A. 1-4: The risk of HIT is lower in the first 1-4 days following heparin exposure. Although thrombocytopenia may develop during this period, it is typically not immune-mediated, and the full development of HIT symptoms generally takes longer (5-14 days). C. 15-30: The risk of HIT does not peak during 15-30 days after heparin exposure. By this time, if HIT has not occurred, the risk significantly decreases. HIT is typically most prominent in the 5-14 day period after exposure, and a delayed onset is not typical. D. 40-60: The risk of HIT at 40-60 days following heparin exposure is exceedingly rare. By this time, the risk of developing HIT would have significantly diminished or resolved, and late-onset HIT is highly unusual.",
      "correct_choice_id": 287125,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38922641705131327/38922641705131327.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38922641705131327/38922641705131327.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 82053,
      "choices": [
        {
          "id": 287128,
          "text": "Type 1"
        },
        {
          "id": 287129,
          "text": "Type 2 A"
        },
        {
          "id": 287130,
          "text": "Type 2 B"
        },
        {
          "id": 287131,
          "text": "Type 3"
        }
      ],
      "text": "Most common subtype of Von Willebrand disease ?",
      "unique_key": "Q8753409",
      "question_audio": null,
      "question_video": null,
      "map_id": 34249706,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Type 1 The most common subtype of Von Willebrand Disease (VWD) is Type 1, which accounts for about 60-80% of cases. Type 1 VWD is characterized by partial quantitative deficiency of von Willebrand factor (VWF, the clotting protein), leading to mild bleeding symptoms. The condition is inherited in an autosomal dominant manner, and affected individuals often have a family history of bleeding disorders. Type 1 is typically diagnosed with lower-than-normal levels of VWF, though the function of the VWF may remain relatively normal. Incorrect Responses: B. Type 2A: Type 2A is a less common subtype of VWD, accounting for around 10-20% of cases. It is characterized by a qualitative defect in VWF, where the protein is present but does not function properly, leading to a more severe bleeding tendency than in Type 1. The bleeding symptoms can be more prominent, but it is not the most common subtype. C. Type 2B: Type 2B is an even rarer form of VWD, making up a small proportion of cases. It involves a gain-of-function mutation in the VWF gene, which causes VWF to bind to platelets more readily, leading to thrombocytopenia (low platelet count). This subtype is associated with more severe bleeding and thrombotic complications, but it is not the most common form. D. Type 3: Type 3 VWD is the most severe form of the disease, characterized by a complete absence of functional von Willebrand factor. It is a rare, autosomal recessive disorder that results in severe bleeding tendencies, often present from early childhood. It is much less common than Type 1.",
      "correct_choice_id": 287128,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6911871705131340/6911871705131340.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6911871705131340/6911871705131340.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 82054,
      "choices": [
        {
          "id": 287132,
          "text": "Romiplostim or eltrombopag"
        },
        {
          "id": 287133,
          "text": "Dexamethasone"
        },
        {
          "id": 287134,
          "text": "Platelet transfusion"
        },
        {
          "id": 287135,
          "text": "IVIG"
        }
      ],
      "text": "A 30-year-old woman with epistaxis for the past few days visits in emergency department. The patient says she has a long history of bleeding episodes. Her menstrual periods are heavy at times. Previous OPD papers mentioned that she has ITP. On examination- Skin: petechiae on both lower extremities. CBC: platelet count 25,000/?L PT, aPTT, INR: all normal. One hour later the patient’s bleeding worsens. There is melena, more petechiae, and haematuria. A repeat CBC shows platelet level at 9000/µL. Which is the fastest way to raise the platelet count in idiopathic thrombocytopenic purpura ?",
      "unique_key": "Q1295322",
      "question_audio": null,
      "question_video": null,
      "map_id": 34517724,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) IVIG works faster than any other method of increasing the platelet count and is more effective. Steroids work by inhibiting the affinity of the macrophage for the Fc end of the antibodies attached to platelets. Platelet transfusions do not work because as soon as the platelets enter the body, they are covered with antiplatelet antibodies and rapidly destroyed. Romiplostim and eltrombopag are thrombopoietin. They stimulate megakaryocyte growth and are given in recurrence even after splenectomy. Rituximab removes CD20 lymphocytes, which make antibodies against platelets. Keynote- mechanism of IVIG in increasing platelet count- Supersaturation of Fc receptors on macrophages. IVIG mechanism is involved entirely with blocking the macrophage. If the macrophage is fully saturated with Fc ends of IVIG or RhO(D) immune globulin (RhoGAM) (anti-D antibodies), there is no room to bind the Fc ends of the immunoglobulins attached to platelets. Clinical pearls- Splenectomy works in ITP by reducing platelet destruction. Platelet transfusion is rarely done for three reasons: 1. Bleeding is rarely severe enough to need platelets. 2. Steroids are usually quite efficacious, starting within hours. 3. Platelets are consumed as soon as you infuse them into the patient.",
      "correct_choice_id": 287135,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1637711698818163/1637711698818163.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1637711698818163/1637711698818163.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}